Pharma Spent $452 Million Lobbying in 2025 as FDA Nominee Faced Senate
Public records show a 432% surge in pharmaceutical spending at White House-connected lobbying firms in the same year a new FDA commissioner was being confirmed — and a peer-reviewed study finds...
In 2025, the pharmaceutical industry reported $452 million in federal lobbying expenditures — the largest single-year total on record, according to OpenSecrets data cited on the official congressional website of Rep. Jake Auchincloss (D-MA). That figure is not the most arresting number in the public record. The more telling one is $9.5 million: the increase in pharmaceutical industry spending directed specifically at three lobbying firms described as 'close to the White House,' whose pharma-related revenue jumped from $2.2 million in 2024 to $11.7 million in 2025 — a 432% year-over-year increase — in the same calendar year that a new FDA commissioner was undergoing Senate confirmation. Both figures come from OpenSecrets disclosures as reported through Auchincloss's office. Neither the three firms nor their specific clients are identified in available public summaries, which is itself a finding worth noting.
The $452 million figure is not an aberration. It is the apex of a sustained, institutionalized expenditure pattern stretching back more than two decades. A peer-reviewed study by Wouters (2020), published in JAMA Internal Medicine (PMC7054854) and cited more than 173 times, documented that the pharmaceutical, biotechnology, and medical device industries spent an average of $233 million per year on federal lobbying across the 1999–2018 period — a total approaching $4.7 billion over twenty years. During the 2009–2012 window alone, the Union of Concerned Scientists analyst Celia Wexler reported the sector's lobbying total exceeded $700 million, surpassing the oil and gas industry's $467 million and the insurance industry's $481 million for the same period. Pharma, in other words, outspends the industries most commonly cited as canonical examples of regulatory capture.
The same Wouters study documents $414 million in pharmaceutical industry electoral contributions across 1999–2018. Of that total, $214 million — roughly 52% — went to congressional candidates specifically, not presidential races. An additional $6 million-plus flowed to members of Congress serving on committees with direct FDA jurisdiction during the 2009–2012 period alone, according to the UCS analysis. The relevant committees include the Senate HELP Committee, Senate Finance Committee, House Energy and Commerce Committee, and House Ways and Means Committee. The UCS report does not individually name the recipients; disaggregated FEC filings would be required to identify them. That data is publicly available and has not been compiled here.
The strategic logic behind the congressional concentration is not difficult to reconstruct from the public record. The Prescription Drug User Fee Act — PDUFA — requires congressional reauthorization approximately every five years. Each cycle involves formal negotiation between FDA leadership and industry representatives over user fee amounts, review timelines, and performance targets. The lobbying disclosure system, governed by the Lobbying Disclosure Act and reported to Congress via lda.senate.gov, would allow any researcher to cross-reference lobbying expenditures against PDUFA reauthorization years (approximately 2002, 2007, 2012, 2017, 2022) to determine whether industry spend spikes in those windows. That analysis has not been performed in available literature. The structural significance of PDUFA is not disputed: it is a statutory mechanism through which the regulated industry formally participates in writing the terms of its own regulatory review.
Beyond the structural architecture, there is direct statistical evidence connecting lobbying expenditure to regulatory outcome. A faculty study published through Merrimack College's ScholarWorks repository, titled 'Two Faces of Corporate Lobbying,' applied logistic regression analysis to FDA drug approval data from 1998 to 2013. The dependent variable was whether a firm received FDA drug approval in a given year. The independent variables included total lobbying dollar amount, a binary indicator for whether the firm lobbied at least one bill, and the total number of bills lobbied, with year fixed effects applied. The results, reported in Table 4 of that paper at conventional statistical significance thresholds, show a positive and statistically significant association between firm-level lobbying expenditure and the probability of receiving FDA drug approval. The study's authors do not claim proof of direct quid pro quo. Possible explanations range from lobbying improving regulatory navigation competence, to lobbying shaping FDA guidance documents in ways that favor lobbying firms' product profiles, to selection effects in which firms with stronger pipelines both lobby more and get approved more. The data cannot distinguish among these mechanisms. It does establish that the relationship exists and is not attributable to chance at conventional confidence levels.
In 2025, concurrent with the record lobbying totals, PhRMA — the industry's primary trade association — ran a seven-figure advertising campaign framing pharmaceutical industry preferences as 'American dominance in biopharmaceutical innovation,' according to Auchincloss's office citing a source familiar with the campaign. The framing mirrors current administration rhetorical priorities around economic sovereignty and national competitiveness. The specific dollar amount beyond 'seven figures,' the outlets targeted, and the internal strategy documents behind the campaign are not available in open-source materials. PhRMA's IRS Form 990 filings, as a 501(c)(6) organization, would disclose expenditure categories. The sole named company-specific regulatory event in the available record involves Eli Lilly, whose FDA product approval in 2025 prompted a response from FDA spokesperson Emily Hilliard stating the decision 'reflected the consensus of the primary review team of career agency scientists.' The specific product approved, and Eli Lilly's lobbying expenditure timeline relative to that approval date, are not identified in available public summaries. Eli Lilly's LDA filings are publicly accessible at lda.senate.gov.
What remains hidden is consequential. The three White House-proximate lobbying firms that received the 432% spending surge are unnamed in public summaries — but are identifiable. Cross-referencing 2024–2025 LDA registrations against firms whose principals held Trump administration positions in either the first or second term, filtered for pharmaceutical clients with 2025 contract initiation dates, would produce a short list. Senate confirmation hearings for the FDA nominee represent one of the few moments when legislators can compel disclosure of communications between regulated industries, executive branch transition teams, and agency leadership — on the record, under oath. Whether that instrument was used, and what it produced, is the next document this investigation requires.